A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials

J Neurooncol. 2019 Aug;144(1):235-237. doi: 10.1007/s11060-019-03219-7. Epub 2019 Jun 25.

Authors

Saba S Shaikh^{1

2}, Priya U Kumthekar³, Nisha A Mohindra³

Affiliations

¹ Northwestern University Fienberg School of Medicine, Chicago, IL, USA. Saba.shaikh@northwestern.edu.
² Northwestern University Fienberg School of Medicine, 676 N. Saint Clair Street, Suite 850, Chicago, IL, 60611, USA. Saba.shaikh@northwestern.edu.
³ Northwestern University Fienberg School of Medicine, Chicago, IL, USA.

PMID: 31240523
DOI: 10.1007/s11060-019-03219-7

No abstract available

Publication types

Letter
Review

MeSH terms

Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy*
Central Nervous System Neoplasms / immunology
Central Nervous System Neoplasms / secondary
Central Nervous System Neoplasms / therapy*
Clinical Trials as Topic / statistics & numerical data*
Humans
Immunotherapy / methods*
Lung Neoplasms / immunology
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Patient Selection*